zealand pharma glp 1 announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial Dapiglutide (program paused) - Pipeline

The most frequently reported adverse effects of GLP-1 receptor agonists are gastrointestinal in nature

In humans, GLP-1R agonism frequently reduces BP

Evolv GLP-1 biomimetic snapshot Evolv GLP-1 Biomimetic is sold direct-to-consumer as a yeast-powered daily supplement delivering the full power of GLP-1 naturally. A 30-tablet bottle costs ~$148

3 Important safety information: Wegovy (semaglutide) is a prescription-only medication for managing obesity

Our personalized assessment quiz allows us to evaluate your health history and determine the most suitable treatment options for you

This rule follows from an April 2025 Executive Order from the Trump administration directing the Assistant to the President for Domestic Policy to reevaluate the role of middlemen to promote a more competitive, efficient, transparent, and resilient pharmaceutical value chain